IVERIC bio – Public Company Spotlight at Ophthalmology Innovation Summit @ AAO 2019

Glenn Sblendorio, CEO & President, speaks about IVERIC bio’s plans to develop gene therapies for orphan inherited retinal diseases.

Plans include a phase 1/2 in 2020 for lead candidate IC-100, a RHO-adRP.

Glenn Sblendorio presented for IVERIC bio during the Public Company Spotlight at OIS@AAO 2019.

REGISTER for our next ophthalmology conference today.